KZR - Kezar Life Sciences, Inc.
| Previous Close | 4.1500 |
| Open | 4.1300 |
| Bid | 3.8000 x 900 |
| Ask | 18.0000 x 800 |
| Day's Range | 3.8200 - 4.4799 |
| 52 Week Range | 3.8200 - 36.3300 |
| Volume | 53,129 |
| Avg. Volume | 115,622 |
| Market Cap | 73.871M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4560 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.33 |
- GuruFocus.com
Frazier Management Llc Buys Translate Bio Inc, Kezar Life Sciences Inc
Investment company Frazier Management Llc (Current Portfolio) buys Translate Bio Inc, Kezar Life Sciences Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Frazier Management Llc. Continue reading...
- American City Business Journals
It’s not just Bloom Energy: Half of last year’s Bay Area IPO stocks are underwater
Half of the 34 businesses from the region that debuted on Wall Street in 2018 are now trading below their initial offering price, and three have experienced bigger percentage drops than Bloom.
- GlobeNewswire
Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiatedPhase 2 PRESIDIO.
- PR Newswire
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
SAN DIEGO , July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued ...
- Benzinga
The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
- GlobeNewswire
Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced positive results from the Phase 1b open-label dose escalation portion of the MISSION study evaluating KZR-616 in patients with systemic lupus erythematosus (SLE). The primary objective of this first-in-patient study is to assess the safety and tolerability of KZR-616. “We are encouraged by the early safety and efficacy data for KZR-616.
- GlobeNewswire
Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- Benzinga
The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kezar Life Sciences, Inc. - KZR
Pomerantz LLP is investigating claims on behalf of investors of Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (KZR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Following this news, Kezar’s stock price fell $6.99 per share, or 41.39%, to close at $9.90 per share on May 28, 2019.
- GlobeNewswire
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that data from the first two cohorts of an open-label dose escalation trial of KZR-616 in patients with systemic lupus erythematosus (SLE) will be featured in a poster presentation at the European League Against Rheumatism (EULAR) 2019 annual meeting taking place in Madrid, Spain June 12-15. The full abstract, which is published on EULAR’s conference website, features preliminary results from the first two cohorts of the Phase 1b portion of the MISSION trial (Modulator of the Immunoproteasome for Systemic Lupus with and without Nephritis), which is evaluating KZR-616 in patients with SLE. Additional details regarding the trial, outcome measures, and patients enrolled will be presented at the meeting.
- Simply Wall St.
Did Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- American City Business Journals
Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.
- GlobeNewswire
Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- Insider Monkey
Here is What Hedge Funds Think About Kezar Life Sciences, Inc. (KZR)
At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]
- GlobeNewswire
Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019Site selection underway for Phase 2 trial of.
- GlobeNewswire
Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 03, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif., March 28, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update
Phase 1b SLE top-line data and Phase 2 LN initiation in Q2 2019Phase 2 trials in up to four additional autoimmune indications to begin 2H 2019First clinical candidate nomination.
- GlobeNewswire
Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616
Kezar Life Sciences, Inc. (KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the initiation of a Phase 1, randomized, double-blind, placebo controlled, single and multiple ascending dose trial to assess the safety, tolerability, pharmacokinetics and target inhibition of a simplified lyophilized formulation of KZR-616. The trial is being conducted in Australia and will enroll up to 72 healthy female subjects. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in a Phase 1b trial, with a Phase 2 trial in lupus nephritis patients expected to initiate during the first half of 2019.
- GlobeNewswire
Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 05, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs
Kezar Life Sciences, Inc. (KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Celia Economides as Senior Vice President of Strategy and External Affairs. Ms. Economides will serve as a member of the management team and executive committee leading Kezar’s overall investor relations, scientific communications, patient advocacy and strategic efforts.
- ACCESSWIRE
These 4 Biotech Stocks are Picking Up Speed
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry is predicated on the notion that, presently, we can do more to create better treatment options and medical technologies to improve the quality of care for those suffering from a myriad of ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Fennec Pharmaceuticals, Inc (FENC), Aimmune Therapeutics, Inc (AIMT), and Kezar Life Sciences, Inc (KZR) are 4 biotech stocks representing companies working towards the advancement of the biotech sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company ready to meet the demands of consumers looking for access to quality primary care.
- GlobeNewswire
Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- American City Business Journals
Here's how much better insiders have profited from this year's IPO boom
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
- GlobeNewswire
Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
